SpyGlass Pharma announced in a press release the American Medical Association’s (AMA) CPT Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant, based on the application submitted for the Bimatoprost Drug Pad-IOL System (BIM-IOL System), in conjunction with established Category I cataract surgery procedure codes.

Category III CPT codes are established by the AMA’s CPT Editorial Panel to describe emerging medical technologies and procedures and to support utilization tracking and data collection that may inform future coverage, reimbursement, and transition to permanent Category I CPT codes. The approved add-on Category III CPT code is:

• +X659T. Attachment and insertion of intraocular drug delivery implant

According to the company, the BIM-IOL System is being evaluated in 2 registrational phase 3 clinical trials—SGP-005 (Rhine) and SGP-006 (Rhone)—for the treatment of elevated intraocular pressure in patients previously diagnosed with open-angle glaucoma or ocular hypertension and a concomitant cataract. Enrollment in both trials remains on track and is expected to be completed in 2027, the company said. GP